Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers

A series of meta-analyses

A. Andriulli, V. Annese, N. Caruso, A. Pilotto, L. Accadia, A. G. Niro, M. Quitadamo, A. Merla, S. Fiorella, G. Leandro

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

OBJECTIVE: To perform metaanalyses of studies on outcome of bleeding ulcers of different proton-pump inhibitors (PPIs) regimens, after stratification of patients by endoscopic stigmata, and analysis of studies with and without endotherapy. METHODS: A total of 35 randomized trials comparing PPIs to placebo and/or H2-receptor antagonists (H2RAs) in 4,843 patients with high-risk endoscopic stigmata were retrieved. Outcomes were rebleeding, surgery, and mortality. RESULTS: Monotherapy with oral or bolus PPIs was superior to placebo and H2RAs in reducing rebleeding in both bleeders and nonbleeders at index endoscopy; the need for surgery was reduced only when compared to H2RAs. In nonbleeders, PPI monotherapy was as effective as a combination of endotherapy with H2RAs. A combination of endotherapy with PPIs was superior to monotherapy in reducing bleeding and surgery, and superior to endotherapy alone in minimizing rebleeding, but not surgery; the benefit was lost when confronted to endotherapy plus H2RAs, whether PPIs were given as infusion or bolus. By pooling data from studies comparing high doses of PPIs as continuous infusion versus regular doses as intermittent bolus, rebleeding, surgery, and mortality were not significantly different. CONCLUSIONS: Combination of endotherapy with either PPIs or H2RAs is indicated for nonbleeding ulcers at endoscopy with the intent to reduce rebleeding and surgery. Its value may extend to bleeding lesions, but current data are scanty. The benefit appears to be independent from route and doses of PPIs, as oral, bolus, or infusional methods are all effective.

Original languageEnglish
Pages (from-to)207-219
Number of pages13
JournalAmerican Journal of Gastroenterology
Volume100
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Endoscopic Hemostasis
Proton Pump Inhibitors
Peptic Ulcer
Meta-Analysis
Histamine H2 Receptors
Hemorrhage
Christianity
Endoscopy
Ulcer
Placebos
Mortality
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers : A series of meta-analyses. / Andriulli, A.; Annese, V.; Caruso, N.; Pilotto, A.; Accadia, L.; Niro, A. G.; Quitadamo, M.; Merla, A.; Fiorella, S.; Leandro, G.

In: American Journal of Gastroenterology, Vol. 100, No. 1, 01.2005, p. 207-219.

Research output: Contribution to journalArticle

Andriulli, A. ; Annese, V. ; Caruso, N. ; Pilotto, A. ; Accadia, L. ; Niro, A. G. ; Quitadamo, M. ; Merla, A. ; Fiorella, S. ; Leandro, G. / Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers : A series of meta-analyses. In: American Journal of Gastroenterology. 2005 ; Vol. 100, No. 1. pp. 207-219.
@article{e4a7d0381f0942e89789bbb814ccfc6b,
title = "Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: A series of meta-analyses",
abstract = "OBJECTIVE: To perform metaanalyses of studies on outcome of bleeding ulcers of different proton-pump inhibitors (PPIs) regimens, after stratification of patients by endoscopic stigmata, and analysis of studies with and without endotherapy. METHODS: A total of 35 randomized trials comparing PPIs to placebo and/or H2-receptor antagonists (H2RAs) in 4,843 patients with high-risk endoscopic stigmata were retrieved. Outcomes were rebleeding, surgery, and mortality. RESULTS: Monotherapy with oral or bolus PPIs was superior to placebo and H2RAs in reducing rebleeding in both bleeders and nonbleeders at index endoscopy; the need for surgery was reduced only when compared to H2RAs. In nonbleeders, PPI monotherapy was as effective as a combination of endotherapy with H2RAs. A combination of endotherapy with PPIs was superior to monotherapy in reducing bleeding and surgery, and superior to endotherapy alone in minimizing rebleeding, but not surgery; the benefit was lost when confronted to endotherapy plus H2RAs, whether PPIs were given as infusion or bolus. By pooling data from studies comparing high doses of PPIs as continuous infusion versus regular doses as intermittent bolus, rebleeding, surgery, and mortality were not significantly different. CONCLUSIONS: Combination of endotherapy with either PPIs or H2RAs is indicated for nonbleeding ulcers at endoscopy with the intent to reduce rebleeding and surgery. Its value may extend to bleeding lesions, but current data are scanty. The benefit appears to be independent from route and doses of PPIs, as oral, bolus, or infusional methods are all effective.",
author = "A. Andriulli and V. Annese and N. Caruso and A. Pilotto and L. Accadia and Niro, {A. G.} and M. Quitadamo and A. Merla and S. Fiorella and G. Leandro",
year = "2005",
month = "1",
doi = "10.1111/j.1572-0241.2005.40636.x",
language = "English",
volume = "100",
pages = "207--219",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers

T2 - A series of meta-analyses

AU - Andriulli, A.

AU - Annese, V.

AU - Caruso, N.

AU - Pilotto, A.

AU - Accadia, L.

AU - Niro, A. G.

AU - Quitadamo, M.

AU - Merla, A.

AU - Fiorella, S.

AU - Leandro, G.

PY - 2005/1

Y1 - 2005/1

N2 - OBJECTIVE: To perform metaanalyses of studies on outcome of bleeding ulcers of different proton-pump inhibitors (PPIs) regimens, after stratification of patients by endoscopic stigmata, and analysis of studies with and without endotherapy. METHODS: A total of 35 randomized trials comparing PPIs to placebo and/or H2-receptor antagonists (H2RAs) in 4,843 patients with high-risk endoscopic stigmata were retrieved. Outcomes were rebleeding, surgery, and mortality. RESULTS: Monotherapy with oral or bolus PPIs was superior to placebo and H2RAs in reducing rebleeding in both bleeders and nonbleeders at index endoscopy; the need for surgery was reduced only when compared to H2RAs. In nonbleeders, PPI monotherapy was as effective as a combination of endotherapy with H2RAs. A combination of endotherapy with PPIs was superior to monotherapy in reducing bleeding and surgery, and superior to endotherapy alone in minimizing rebleeding, but not surgery; the benefit was lost when confronted to endotherapy plus H2RAs, whether PPIs were given as infusion or bolus. By pooling data from studies comparing high doses of PPIs as continuous infusion versus regular doses as intermittent bolus, rebleeding, surgery, and mortality were not significantly different. CONCLUSIONS: Combination of endotherapy with either PPIs or H2RAs is indicated for nonbleeding ulcers at endoscopy with the intent to reduce rebleeding and surgery. Its value may extend to bleeding lesions, but current data are scanty. The benefit appears to be independent from route and doses of PPIs, as oral, bolus, or infusional methods are all effective.

AB - OBJECTIVE: To perform metaanalyses of studies on outcome of bleeding ulcers of different proton-pump inhibitors (PPIs) regimens, after stratification of patients by endoscopic stigmata, and analysis of studies with and without endotherapy. METHODS: A total of 35 randomized trials comparing PPIs to placebo and/or H2-receptor antagonists (H2RAs) in 4,843 patients with high-risk endoscopic stigmata were retrieved. Outcomes were rebleeding, surgery, and mortality. RESULTS: Monotherapy with oral or bolus PPIs was superior to placebo and H2RAs in reducing rebleeding in both bleeders and nonbleeders at index endoscopy; the need for surgery was reduced only when compared to H2RAs. In nonbleeders, PPI monotherapy was as effective as a combination of endotherapy with H2RAs. A combination of endotherapy with PPIs was superior to monotherapy in reducing bleeding and surgery, and superior to endotherapy alone in minimizing rebleeding, but not surgery; the benefit was lost when confronted to endotherapy plus H2RAs, whether PPIs were given as infusion or bolus. By pooling data from studies comparing high doses of PPIs as continuous infusion versus regular doses as intermittent bolus, rebleeding, surgery, and mortality were not significantly different. CONCLUSIONS: Combination of endotherapy with either PPIs or H2RAs is indicated for nonbleeding ulcers at endoscopy with the intent to reduce rebleeding and surgery. Its value may extend to bleeding lesions, but current data are scanty. The benefit appears to be independent from route and doses of PPIs, as oral, bolus, or infusional methods are all effective.

UR - http://www.scopus.com/inward/record.url?scp=13744262554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13744262554&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2005.40636.x

DO - 10.1111/j.1572-0241.2005.40636.x

M3 - Article

VL - 100

SP - 207

EP - 219

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 1

ER -